Moneycontrol PRO
Upcoming Webinar:Join us for 'The Future Techshot' on Sept 22, 10:30am to gain insights into role of tech in streamlining businesses. Register Now!
you are here: HomeNewsBusiness

Buy Laurus Labs; target of Rs 550: ICICI Direct

ICICI Direct is bullish on Laurus Labs has recommended buy rating on the stock with a target price of Rs 550 in its research report dated April 30, 2021.

May 25, 2021 / 05:07 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Laurus Labs

Q4 revenues grew 68.3% to Rs 1412 crore with strong growth across segments. Results were driven by 88.0% YoY jump in API segment to Rs 797 crore amid strong traction in antiviral APIs to Rs 569 crore (2.1x YoY) driven by higher volume of first and second line products. Formulations revenue grew 60.9% YoY to Rs 430 crore on the back of higher tender business from LMIC and higher volumes from the US and Europe. CRAMS business grew 19.0% YoY to Rs 176 crore. EBITDA margins improved 1059 bps to 33.4% (vs. 22.9% in Q4FY20) due to better product mix and improved operating leverage. Subsequently, EBITDA grew 146.2% YoY to Rs 472 crore. PAT was up 169.3% YoY at Rs 297 crore in line with a strong operational performance


We maintain BUY rating with a target price of Rs 550 (vs. Rs 440 earlier) based on 20x of FY23E EPS of 27.4.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: May 25, 2021 05:07 pm

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark